Cooptation of Dr. Mathieu Simon as new independent Board Director
- Karen Aiach appointed Chair of the Board of Directors
PARIS, France, – 22 May 2019, at 06:00pm CEST – Lysogene (FR0013233475 – LYS), a leading Phase 2/3 biopharmaceutical company specializing in gene therapy technology applied to central nervous system (CNS), today announced new appointments to the Board of Directors.
Dr. Mathieu Simon has been appointed by cooptation as an independent director. A graduate in internal medicine from the Faculty of Medicine of Paris VII, Dr. Simon is Senior Strategic Advisor at Messier Maris & Associés, an international investment bank. He is also an independent Director of Vaximm AG, LNC SA, member of the Supervisory Board of Affimed and non-executive member of Idorsia Board of Directors. Moreover, Dr. Simon is an advisor to the European Commission – Research and Innovation. He previously held positions of Executive Vice President, Chief Operating Officer of Cellectis, CEO of Cellectis Therapeutics and CEO of Ectycell; Senior Vice President and Head of Global Pharmaceutical Operations at Pierre Fabre SA, as well as general management and senior corporate roles at Wyeth Pharmaceuticals. He was also Chairman of the Board of Directors of Cellartis AB.
In addition, Karen Aiach, Founder and Chief Executive Officer of Lysogene, has been appointed Chair of the Board of Directors. Ms. Aiach succeeds Annette Clancy who held the post of Chair since 2015. Ms. Clancy will remain on the Board as an independent Director.
“It has been a pleasure to chair Lysogene over the past 4 years and help guide the company through its public listing on Euronext and very importantly secure an excellent partnership with Sarepta last year. This partnership provides an opportunity for MPS IIIA patients to receive a potential life altering treatment and sets the Company on a growth trajectory to becoming a leading gene therapy company in Europe,” said Annette Clancy.
“We would like to thank Ms. Clancy for her important contribution as Chair of the Board and look forward to continuing to work with her as a director,” said Karen Aiach.
“At the same time, we are delighted to welcome Dr. Simon to the Board of Directors, during this period of exciting progress in our pipeline including our ongoing international Phase 3 clinical trial at Lysogene. Dr. Simon brings a wealth of experience and strategic vision to the company.”
Lysogene’s Board of Directors is now composed exclusively of independent directors, with the exception of Karen Aiach.
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1-2 clinical trial in GM1 Gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the development strategy for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.
Mathilde Bohin / Emmanuel Huynh NewCap
+ 33 1 44 71 94 95
Lysogene’s forward-looking statements
This press release may contain forward-looking statements, especially on the Company’s progress of its Phase 2/3 clinical trial. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are subject to (i) change without notice, (ii) factors beyond the Company’s control and (iii) the Company’s financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as “objective”, “believe”, “anticipate”, “foresee”, “aim”, “intend”, “may”, “anticipate”, “estimate”, “plan”, “project”, “will”, “may”, “probably”, “should”, “could” and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that may, if any, cause actual results, performance or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward- looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including the Company’s 2018 registration document, registered with the AMF on 29 April 2019 under number R. 19-016, as well as in the documents and reports to be published subsequently by the Company. In addition, these forward-looking statements speak only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company’s update of one or more forward- looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements.
This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company’s shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this press release are required to inquire about and comply with these restrictions.